Shares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase …
After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …
J.P.
ACADIA Pharmaceuticals (NASDAQ:ACAD) just got hit with a bad bullet: a CNN research report questioning lead asset Nuplazid’s risk/reward as a treatment of …
Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with …
ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street’s top analysts impressed in the upshot. What commercial …
One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the drug maker announced the presentation of data from the …
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer’s disease psychosis at the …
